Therapeutic Asset Ratings

176 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Rmc-4630 Non-Small Cell Lung Cancer	The Netherlands Cancer Institute	P2	CCC (51)
Vistusertib Non-Small Cell Lung Cancer	AstraZeneca	P2	CCC (51)
bi 853520 Non-Small Cell Lung Cancer	InxMed (Shanghai) Co., Ltd.	P3	CCC (50)
Foritinib Succinate Non-Small Cell Lung Cancer	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	P3	CCC (50)
Iruplinalkib Non-Small Cell Lung Cancer	Peking University Shenzhen Hospital	P2	CCC (50)
Shr-1826 Non-Small Cell Lung Cancer	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P2	CCC (50)
Zelenectide Pevedotin Non-Small Cell Lung Cancer	BicycleTx Limited	P2	CCC (50)
Bgb-15025 Non-Small Cell Lung Cancer	BeiGene	P2	CCC (48)
Immunoglobulin G1 [247-alanine,248-glutamic acid,250-alanine,343-serine,344-serine,de-C-terminal-lysine], anti-(human T cell immunoreceptor with Ig and ITIM domains) (human monoclonal BMS-986207 ?1-chain), disulfide with human monoclonal BMS-986207 ?-chain, dimer Non-Small Cell Lung Cancer	Bristol-Myers Squibb	P2	CCC (48)
immunoglobulin G1-kappa, anti-[Homo sapiens TNFRSF4 (tumor necrosis factor receptor (TNFR) superfamily member 4, OX40, CD134)], humanized monoclonal antibody Non-Small Cell Lung Cancer	BeiGene	P2	CCC (48)
Romiplostim Non-Small Cell Lung Cancer	Peking University People's Hospital	P2	CCC (48)
Grt-C903 Non-Small Cell Lung Cancer	National Cancer Institute (NCI)	P1/2	CCC (48)
Grt-R904 Non-Small Cell Lung Cancer	National Cancer Institute (NCI)	P1/2	CCC (48)
Immunoglobulin G4 [234-proline], anti-(human protein GARP-transforming growth factor ?1 complex) (human monoclonal ABBV-151 ?4-chain), disulfide with human monoclonal ABBV-151 ?-chain, dimer Non-Small Cell Lung Cancer	AbbVie	P2/3	CCC (48)
LEUPROLIDE Non-Small Cell Lung Cancer	Jinzhou Medical University	P1/2	CCC (48)
Ribociclib Non-Small Cell Lung Cancer	Novartis Pharmaceuticals	P1/2	CCC (48)
Syhx2011 Non-Small Cell Lung Cancer	Shanghai Chest Hospital	P2/3	CCC (48)
Zilongjin Non-Small Cell Lung Cancer	Kong Fanming	P2/3	CCC (48)
Zoladex Non-Small Cell Lung Cancer	Novartis Pharmaceuticals	P1/2	CCC (48)
Absk043 Non-Small Cell Lung Cancer	Abbisko Therapeutics Co, Ltd	P2	CC (46)
Absk061 Non-Small Cell Lung Cancer	Abbisko Therapeutics Co, Ltd	P2	CC (46)
Alpha Tocopherol Non-Small Cell Lung Cancer	University Health Network, Toronto	P2	CC (46)
es102 Non-Small Cell Lung Cancer	Elpiscience (Suzhou) Biopharma, Ltd.	P2	CC (46)
Febuxostat Non-Small Cell Lung Cancer	Maastricht University Medical Center	P2	CC (46)
fl-101 Non-Small Cell Lung Cancer	Flame Biosciences	P2	CC (46)

Showing 51 to 75 of 176 assets

PreviousPage 3 of 8Next